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Abstract
We recently reported a new class of inhibitors of the chymotrypsin-like serine protease NS3 of the hepatitis
C virus. These inhibitors exploit the binding potential of the S site of the protease, which is not generally
used by the natural substrates. The effect of prime-site occupancy was analyzed by circular dichroism
spectroscopy and limited proteolysis-mass spectrometry. Generally, nonprime inhibitors cause a structural
change in NS3. Binding in the S site produces additional conformational changes with different binding
modes, even in the case of the NS3/4A cofactor complex. Notably, inhibitor binding either in the S or S
site also has profound effects on the stabilization of the protease. In addition, the stabilization propagates
to regions not in direct contact with the inhibitor. In particular, the N-terminal region, which according to
structural studies is endowed with low structural stability and is not stabilized by nonprime inhibitors, was
now fully protected from proteolytic degradation. From the perspective of drug design, P-P inhibitors take
advantage of binding pockets, which are not exploited by the natural HCV substrates; hence, they are an
entry point for a novel class of NS3/4A inhibitors. Here we show that binding of each inhibitor is associated
with a specific structural rearrangement. The development of a range of inhibitors belonging to different
classes and an understanding of their interactions with the protease are required to address the issue of the
most likely outcome of viral protease inhibitor therapy, that is, viral resistance.
Keywords: Hepatitis C virus NS3 serine protease; near-UV circular dichroism; limited proteolysis-mass
spectrometry; protease inhibitors; conformational changes
The hepatitis C virus causes a predominantly chronic viral
infection that affects ∼3% of the world population, for
which existing antiviral treatments present problems of tox-
icity and limited effectiveness. A key role in the maturation
of the hepatitis C virus is due to the viral serine protease that
is encoded in the N-terminal domain of the multifunctional
NS3 protein. Therefore, the NS3 protein is one of the most
important targets for drug development against HCV. Al-
though NS3 shows proteolytic activity of its own, the effi-
cient processing of all the cleavage sites, necessary for viral
maturation, is strictly dependent on the formation of a fully
competent proteolytic complex between NS3 and another
viral protein, NS4A.
Structural studies (Kim et al. 1996; Love et al. 1996; Yan
et al. 1998; Barbato et al. 1999; Yao et al. 1999), as well as
spectroscopic (Bianchi et al. 1997; Orru` et al. 1999) and
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We follow the nomenclature of Schechter and Berger (1967) in desig-
nating the cleavage sites as P6-P5-P4-P3-P2-P1 . . . P1-P2-P3-P4, etc.,
with the scissile bond between P1 and P1 and the C terminus of the
substrate on the prime site. The binding sites on the enzyme corresponding
to residues P6-P5-P4-P3-P2-P1 . . . P1-P2-P3-P4 are indicated as S6-
S5-S4-S3-S2-S1 . . . S1-S2-S3-S4, etc.
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kinetic analysis (Landro et al. 1997), have highlighted that
binding of the cofactor NS4A causes a structural rearrange-
ment of NS3, which results in a fully proteolytically com-
petent enzyme. Complex formation has a key role in the
stabilization of the N-terminal domain of the enzyme. This
region comprises the S site, which is part of the substrate
binding site and it contains residues of the catalytic machin-
ery. The substrate binding region is shallow and entirely
solvent exposed and as a consequence the enzyme requires
at least a decapeptide substrate (Steinkühler et al. 1996;
Urbani et al. 1997). The design of inhibitors is therefore
particularly challenging.
This notwithstanding, several potent peptide inhibitors of
the NS3/4A protease have been described, essentially based
on the N-terminal cleavage product (Ingallinella et al. 1998;
Llinàs-Brunet et al. 1998). This class of competitive inhibi-
tors takes advantage of binding in the S subsite of the en-
zyme in a well-defined extended conformation as observed
for other proteolytic enzymes (Rich 1990; Bianchi et al.
1999; Cicero et al. 1999; LaPlante et al. 1999a; Barbato et
al. 2000). In particular, circular dichroism spectroscopy and
the joint use of limited proteolysis and mass spectroscopy
showed that product-based inhibitors bind according to an
induced-fit mechanism (Bianchi et al. 1999). Different bind-
ing modes could be achieved in the absence of cofactor,
whereas in the presence of cofactor, all inhibitors showed
the same binding mode to NS3, with a small rearrangement
of protease tertiary structure. Cofactor binding induces a
NS3/4A conformation that is already, but not entirely, pre-
organized for substrate binding, affecting the S site, as well
as the S site. Conversely, occupancy of the substrate binding
site by the product-based inhibitor induces an overall sta-
bilization of the protease complex, also influencing the re-
gion involved in cofactor binding. Accordingly, recent
NMR solution studies of NS3/P inhibitor complexes sug-
gested that the proteolytic competent state of the NS3 pro-
tease is only achieved through complexation of both the
cofactor and the substrate (Barbato et al. 2000).
At variance with the P region, very little is known about
the interaction of the P region of the substrate with the S
region of the enzyme. Enzymological studies (Landro et al.
1997; Urbani et al. 1997; Zhang et al. 1997) highlighted
that, differently from the P region, the P region of the
substrate is important for catalysis although it contributes
very poorly to ground-state binding to the enzyme. Accord-
ingly, peptides derived from the P region of the substrates
do not bind to the enzyme. Despite that, on the basis of the
structural information available, the S subsite of the NS3/
4A shows the presence of pockets whose binding potential
was exploited by us, leading to the discovery of a novel
class of substrate-derived peptide inhibitors (Ingallinella et
al. 2000). These competitive inhibitors span from P6 to P4,
therefore also taking advantage of binding in the S site of
the enzyme. In this study this series of inhibitors was se-
lected as a structural probe to gain insight into the binding
mechanism in the S region of the NS3 protease domain
from the HCV J strain. As for product-based inhibitors (Bi-
anchi et al. 1999), we used circular dichroism spectroscopy
and the combination of limited proteolysis and mass spec-
trometry to study the substrate binding site and the effect of
inhibitor binding on the protease tertiary structure.
Results
Inhibitors used in this study
In our previous work (Ingallinella et al. 2000) we reported
a series of peptide inhibitors of the NS3 protease, which
comprise both the P and the P regions. The decapeptide
inhibitors used in this study span from P6 to P4. Their
sequences and inhibitory potencies are reported in Table 1.
These are noncleavable peptides incorporating chemical
changes of the putative scissile bond P1-P1 in order to
prevent proteolysis by NS3. The P1 residue consists of a
secondary amino acid such as proline, as in PepB and PepC.
The proline residue introduces a distortion of the putative
cleavage site, thus impairing cleavage as suggested by Lan-
dro et al. (1997). On the other hand, the inhibitor PepD
contains a suboptimal P1 residue and a methyl group on the
N-amide between P1 and P1 (Ingallinella et al. 2000). All
three peptides share the same sequence in the P region ob-
tained by investigation by combinatorial chemistry of hexa-
peptide product inhibitors binding to NS3 (Ingallinella et al.
1998). PepD and PepB are decapeptides with the residues of
the P region based on the natural viral cleavage sites 4A/B
and 5A/B. In particular the P region of PepD is based on
the 4B N-terminal region Ala-Ser-His-Leu. In PepB the P
sequence Pro-Ser-Nle-Leu resembles the 5A/B sequence
with the isosteric substitution of the methionine for norleu-
cine, the replacement of the aromatic Tyr with the 4B Leu
residue, and the Proline at the P1 position. Also PepC
shows the same sequence homology in positions P6-P1 as
for PepB, but in this peptide, P2 and P3 are replaced with
Table 1. NS3-inhibitors spanning P6–P1 and P6–P4 analyzed
in this study by circular dichroism (CD) spectroscopy and
limited proteolysis mass spectrometry (MS)
Peptide Sequencea IC50 (nM)b
A Asp-glu-Leu-Ile-Cha-Cys-OH 15
B Asp-glu-Leu-Ile-Cha-Cys-Pro-Nle-Ser-Leu 10
C Asp-glu-Leu-Ile-Cha-Cys-Pro-Cha-Asp-Leu <0.2
D Asp-glu-Leu-Ile-Cha-Abu-(Me)Ala-Ser-His-Leu 5000
a Abbreviations: Cha, -cyclohexylalanine; glu, D-glutamic acid; Nle,
Norleucine. N-Methylation of the amide nitrogen is indicated with an (Me)
before the three letter code of the amino acid.
b IC50 values for NS3/Pep4A protease were determined as described in
Ingallinella et al. 1998. Under our experimental conditions, Ki∼0.5 IC50
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residues obtained by combinatorial chemistry studies of the
P region in the context of decapeptide sequences (Ingal-
linella et al. 2000). As indicated in Table 1, PepB and PepC
show >100-fold difference in their inhibitory potencies.
This difference reflects the contribution in binding of the
optimized P2 and P3. To compare the results of this study
with those previously obtained on P-based inhibitors (Bian-
chi et al. 1999) and to evaluate the contribution of the P
region, the hexapeptide PepA was used as a control peptide
spanning P6-P1 and with the same sequence in the P-region.
In the P-based inhibitors the C-terminal carboxylate of the
P1 residue is one of the main contributors to the binding
energy, a contact which lacks in the P-P inhibitors.
Limited proteolysis-mass spectrometry
The limited proteolysis-mass spectrometry technique is a
useful tool for the structural analysis of proteins (Zappa-
costa et al. 1996). This approach is based on the evidence
that exposed, weakly structured, and flexible regions of a
protein can be recognized by a proteolytic enzyme. Here we
employed the limited proteolysis by chymotrypsin to inves-
tigate the interaction of different hexa- and decapeptide in-
hibitors with the NS3 protease. The experiments were car-
ried out on the binary and ternary complexes in which each
inhibitor was incubated with the isolated NS3 or the NS3/
Pep4A heterodimer, respectively. The results were com-
pared with those previously obtained on NS3 (Bianchi et al.
1999; Orru` et al. 1999; Urbani et al. 1999). The differences
in the proteolytic patterns were analyzed to identify the
protein regions involved in the molecular interactions
(Scaloni et al. 1998; Atkinson et al. 2000). Particularly, the
specific conformational changes induced in the three-di-
mensional structure of NS3 by the differently optimized P
and P regions of the inhibitors were studied.
In all experiments, formation of the complexes was per-
formed by incubating NS3 or the NS3/Pep4A heterodimer
with a 10:1 molar excess of individual peptide inhibitors at
pH 7.5 and 25°C for 15 min prior to the proteolytic enzyme
addition. Chymotrypsin was selected as conformational
probe because previous experiments had shown that this
enzyme was able to provide structural information on dif-
ferent regions of NS3 (Bianchi et al. 1999; Orru` et al. 1999;
Urbani et al. 1999). The extent of the enzymatic hydrolyses
was monitored on a time-course basis by sampling the in-
cubation mixtures at appropriate time intervals, followed by
high performance liquid chromatography (HPLC) fraction-
ation of the fragments generated. Individual chromato-
graphic peaks were manually collected and identified by
ESMS, leading to the assignment of the preferential cleav-
age sites.
Figure 1 shows the ribbon representation of the crystal
structure of the NS3/Pep4A complex (Yan et al. 1998). The
backbone of the decapeptide inhibitor PepC has been mod-
eled by energy minimization and molecular dynamics (In-
gallinella et al. 2000). In this figure, the chymotrypsin sen-
sitive sites in the NS3 structure have been highlighted.
First the topology of the binary complexes between NS3
and the two decapeptide inhibitors B and C was analyzed.
Figure 2 shows the HPLC profiles of the aliquots withdrawn
following 60 min of chymotrypsin incubation of the com-
plexes NS3/PepB (Fig. 2A) and NS3/PepC (Fig. 2B). When
these results were compared with those obtained on the
isolated NS3 protease reported in Table 2 (Orru` et al. 1999),
a number of considerations could be drawn. A higher chy-
motrypsin to NS3 substrate ratio was needed in all experi-
ments with the inhibitors (from 1:150 for the NS3 to 1:100
for the inhibitor complexes), suggesting that the binding of
inhibitors increased the overall compactness of the NS3
protease. The distribution of the preferential proteolytic
sites observed in the presence of PepB (Fig. 2A) was very
similar to that displayed by the isolated protein (Table 2). In
particular the preferential chymotryptic sites were observed
at positions Tyr 6, Leu 21, and Leu 36, as indicated by the
rapid appearance of the two complementary peptide frag-
ments 2–6 and 7–186 (peaks 1 and 10 in Fig. 2A) and of
fragments 7–21, 22–186, 22–36, 37–186, (peaks 7, 2, 8, and
9 in Fig. 2A, respectively). All these sites are located in the
NS3 N-terminal domain, a region that is directly involved in
the cofactor NS4A binding. Further cleavages were ob-
served in the substrate binding site, within the C-terminal
domain of the NS3 protease, at Tyr 134, Phe 154, and Cys
159, highlighted by the peptide fragments 135–154, 155–
Fig. 1. Ribbon representation of the backbone of the crystal structure of
the NS3 protease/Pep4A complex (Yan et al. 1998). A gray ribbon is used
for the backbone of the NS3 protease and a magenta ribbon for Pep4A. The
protease residues of the catalytic triad are represented in yellow sticks. The
backbone of a decapeptide inhibitor was modeled by energy minimization
and molecular dynamics (Ingallinella et al. 2000). The peptide is shown as
a stick presentation, with the P region in green and the P in blue. The red
spheres indicate the chymotrypsin sensitive proteolytic sites in the NS3
structure.
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179, and 160–179 (peaks 6, 5, and 4 in Fig. 2A, respec-
tively).
Conversely, a complete protection of most of the prefer-
ential proteolytic sites was observed for the NS3/PepC com-
plex (Fig. 2B) with no evidence of processing at Leu 21,
Leu 36, and Tyr 134. In particular the protection of Leu 36
could be also observed in the NS3/Pep4A complex (Orru` et
al. 1999), suggesting a similar role of Pep4A and the P
region of PepC in stabilizing this region. A lower suscep-
tibility toward proteolysis was also observed for the other
sites in the substrate binding region, Phe 154 and Cys 159.
However, in these experimental conditions, Tyr 6 was
still recognized by chymotrypsin with nearly the same ki-
netics as in the isolated protein, as indicated by the rapid
appearance of the two complementary fragments 2–6 and
7–186 (peaks 1 and 10 in Fig. 2B, respectively). This find-
ing suggests that the binding of PepC strongly affects the
conformation of NS3, inducing an increase in the rigidity
and compactness of both protein domains. However, the
presence of the peptide fragments 160–179 and 155–179
(peaks 4 and 5, respectively), indicated that in the inhibitor/
NS3 complex there is a certain accessibility of the active site
The same approach was employed to investigate the con-
formational changes occurring in NS3 when each of the
peptide inhibitors listed in Table 1 was incubated with the
protease in the presence of its cofactor Pep4A. The results
were then compared with the data obtained on the binary
complexes described above and with those previously re-
ported on the NS3/Pep4A heterodimer (Orru` et al. 1999).
Generally the binding of inhibitors induces an overall sta-
bilization of the cofactor/NS3 complex. This is again sug-
gested by the increase in the enzyme/substrate NS3 ratio,
needed to observe proteolysis (from 1:150 for the NS3/
Pep4A to 1:100 for the inhibitor complexes). When the
ternary complex NS3/Pep4A/decapeptide B was examined,
the pattern of the preferential chymotryptic sites was almost
identical to that observed for the NS3/Pep4A complex
(Table 2) and to that observed in the analysis of the NS3/
PepB binary complex described above. The only exception
concerned the absence of cleavage at Leu 36, which is
known to be protected by the presence of the Pep4A cofac-
tor (Orru` et al. 1999). However, the binding of the inhibitor
B to the NS3/4A complex induces partial protection of resi-
dues located in the substrate binding site, Tyr 134, Phe 154,
and Cys 159 and of the region located at the extreme N-
terminal portion of NS3 with a decreased kinetics of hydro-
lysis at Tyr 6. In Figure 3A and Table 2 for comparison, the
effect for the ternary complex with the P-based-only inhibi-
tor PepA is reported. The same protections, as for PepB, are
also shown for PepA, as indicated by the decrease in the
number of the fragments released in the chromatogram.
The comparison between PepA and PepB (Table2) high-
lights that there is not an evident role in the stabilization by
Table 2. Preferential cleavage sites detected on NS3 and NS3/Pep4A complex either in the absence or in the presence of a 10:1
molar excess of peptide inhibitors
Cleavage
site NS3
NS3 +
PepB
NS3 +
PepC NS3/4A
NS3/4A +
PepA
NS3/4A +
PepB
NS3/4A +
PepC
Tyr 6 ++++ ++++ ++++ ++++ ++ ++ +
Leu 21 +++ +++ − +++ +++ +++ −
Leu 36 +++ +++ − − − − −
Tyr 134 ++ ++ − ++ − + −
Phe 154 ++ ++ + ++ − + −
Cys 159 ++ ++ + ++ − + −
Different cleavage sites were classified merely on qualitative kinetic evaluation.
Fig. 2. Reverse-phase HPLC analysis of NS3/PepB (A) and NS3/PepC (B)
complexes digested with chymotrypsin under controlled conditions using
an enzyme/substrate ratio of 1:100 (w/w) in the presence of a 1:10 molar
excess of each peptide. Individual fractions were collected and analyzed by
ESMS. The CHAPS peak is marked with an asterisk; peaks corresponding
to the inhibitor PepB and PepC are also indicated.
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the binding of the P region of PepB. Moreover, for PepA,
complete protection was observed for residues Tyr 134, Phe
154, and Cys 159 at the active site, probably as a result of
the strong interaction of the C-terminal carboxylate in the
oxyanion hole. This important binding determinant lacks in
the P-P decapeptide inhibitors. In both ternary complexes,
the N-terminal region of NS3 is still endowed with confor-
mational freedom, showing proteolytic accessibility at Tyr 6
and Leu 21. However, a highly compact ternary complex
was obtained with the inhibitor PepC. Figure 3B shows the
HPLC profiles of the aliquots withdrawn after 60 min of
chymotrypsin digestion of the ternary complex NS3/Pep4A/
PepC. In this case no peptide fragments formed, indicating
that all the chymotrypsin sensitive sites Tyr 6, Leu 21, Leu
36, and Tyr 134, Phe 154, and Cys 159 were completely
protected. In particular only a tiny amount of the peptides
3–6 and 7–186 was detected after 1-h incubation, showing
that even Tyr 6 was not accessible. These results indicate
that the binding of PepC caused an increase in the compact-
ness of the inhibitor NS3/Pep4A complex with a concomi-
tant decrease in flexibility.
To summarize our results, both the P-based and P-P-
based inhibitors, as well as the cofactor, have a specific role
in the stabilization of the NS3 structure. In particular if we
compare the sequences of PepA, PepB, and PepC (Table 1)
and their effect on the stabilization of the corresponding
complexes (Table 2), we can easily figure out that the op-
timized binding P region, Pro-Cha-Asp-Leu, has a specific
role in the stabilization of the N-terminal region and in
particular of the two N-terminal -strands, which are in
close contact with the cofactor Pep4A, as shown by the
crystal structure in Figure 1.
Circular dichroism spectroscopy
The near-UV circular dichroism spectroscopy was em-
ployed as a structural probe to study the effect of binding of
the inhibitors to the viral serine protease NS3. In the near-
UV region between 250 and 320 nm, the CD spectrum of a
protein is contributed by the aromatic side chains and it is
characteristic of the protein tertiary structure. The near-UV
CD spectrum of a protein is recognized as a useful tech-
nique for studying protein conformation and ligand binding.
In this study, the near-UV CD spectroscopy was used to
study the binding of the decapeptide inhibitors, spanning
P6-P4, to the NS3 protease either in the presence or in the
absence of 4A cofactor. The decapeptides selected in this
study do not contain any aromatic residues so that any con-
tribution in the near-UV CD region is due to the protease,
namely two tryptophans and five tyrosines in the case of
NS3. Any change in this region reflects an effect on the
overall enzyme tertiary structure.
The results obtained on the decapeptide inhibitors were
compared with those previously reported for P-spanning
inhibitors. In our previous studies (Bianchi et al. 1997,
1999) we showed that cofactor complexation produces a
large change in the near-UV CD spectrum of NS3 and there-
fore a rearrangement of tertiary structure. The P-region in-
hibitor binding site is contained in the C-terminal domain,
whereas the P binding site is in the N-terminal domain.
Despite the fact that the C-terminal domain is thought to be
well organized structurally even in the absence of cofactor,
we showed that the binding of P-based inhibitors to NS3
occurs according to an induced-fit mechanism and that vari-
ous binding modes are apparent. Conversely in the presence
of cofactor, all the P inhibitors bind to NS3, showing the
same binding mode with a small rearrangement of NS3
tertiary structure.
Effect of decapeptide inhibitors on NS3
As already studied for the hexapeptides P-based inhibitors,
we first analyzed how the P-P spanning decapeptide in-
hibitors affect the tertiary structure of the enzyme in the
absence of the cofactor. Complex formation between NS3
and each inhibitor was followed in 15% glycerol, 2%
CHAPS, 3 mM DTT, and 50 mM phosphate buffer, pH 7.5
at a protease concentration of 60 M.
To study whether binding of P region inhibitor has any
effect on the protease tertiary structure, we first compared
two inhibitors that share the same P sequence but differ in
the presence of the P part. In particular, PepA is a hexa-
Fig. 3. Reverse-phase HPLC analysis of NS3/4A/PepA (A) and NS3/4A/
PepC (B) ternary complexes incubated with chymotrypsin under controlled
conditions using an enzyme/substrate ratio of 1:100 (w/w). Individual frac-
tions were collected and analyzed by ESMS. The CHAPS peak is marked
with an asterisk and those accounting for Pep4A and its proteolytic frag-
ments are marked with P; peaks corresponding to the inhibitor PepB and
PepC are also indicated.
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peptide spanning from P6-P1; PepC is a decapeptide from
P6 to P4. Each inhibitor induces major changes in the
near-UV CD spectrum of the protease, as shown in Figure
4. The resulting spectra for the two NS3/inhibitor com-
plexes differ in the overall range, suggesting that binding in
the S site of the enzyme can induce additional conforma-
tional rearrangements apart from those observed for the P
region alone. Recent structural data by NMR have shown
that the structural organization of the N-terminal domain,
which contains the S site, is strongly dependent on the
complexation to 4A. However, from these data it is evident
that the decapeptide inhibitors can bind the flexible region
of the N-terminal domain of the enzyme, inducing some
structural organization.
In Figure 5 we compare the near-UV spectra for other
decapeptide inhibitor/NS3 complexes, in particular for
PepB, PepC, and PepD. Any inhibitor binding induces large
differences in the overall range of the CD spectrum of the
protease. Moreover these rearrangements differ among in-
hibitors, which in this case have different P sequences. So
in the absence of cofactor, binding in the S site still en-
dowed with a large conformational freedom is linked to the
stabilization of various states of the enzyme. Again these
data strongly suggest that besides the effect of the cofactor,
there is also a key role played by both regions P and P of
the substrate in the structural organization and activation of
the viral enzyme.
In particular, in the case of PepB and PepC, the two
peptide sequences differ only in residues at the P site. Here
the comparison of the differences of the near-UV CD spec-
tra of the two inhibitor/NS3 complexes reflects simply the
effects of the different P regions of different potencies,
natural sequence versus combinatorially optimized, on the
tertiary structure of the enzyme.
Effect of decapeptide inhibitors on the
NS3/Pep4A complex
In our previous work (Bianchi et al. 1999), we showed that
in the case of P inhibitors, the binding to the NS3/4A occurs
according to an induced-fit model, as suggested by a modest
change in the overall CD spectrum of the NS3/4A protease.
We compared the effect of many P inhibitors differing in
sequence and potency. Because the spectra for all the P-in-
hibitor/NS3/4A complexes are superimposable, binding is
compatible with just one mode for the different P inhibitors.
Despite so many variations, all the product inhibitors then
seem to fall in the same binding class. In particular the same
effect was observed for PepA, which shares the same P
region of the decapeptides used in this study (Fig. 6; Bianchi
et al. 1999).
The effect of the decapeptide PepC binding to the NS3J/
Pep4A protease is shown in Fig. 6. The spectrum of the
complex differs in the region between 250 and 290 nm from
that of NS3/4A and also from the PepA/NS3/4A complex.
These results suggest that the binding of the PepC in the S
and S site occurs through an induced-fit mechanism with a
rearrangement of tertiary structure of NS3/4A. The P re-
gion has a role in determining the structural change. In fact,
binding in the S site produces an additional structural re-
organization with respect to binding in the S site only.
In Figure 7 we can compare the near-UV CD spectra of
ternary complexes for other decapeptide inhibitors from
Table 1. Contrary to what was observed for S-binding in-
hibitors, the spectra for various decapeptide complexes are
Fig. 4. Inhibitor-induced conformational change of NS3 as detected by
near-UV circular dichroism in 15% glycerol, 2% CHAPS, 3 mM DTT, and
50 mM phosphate buffer at pH 7.5. The spectrum of the uncomplexed
protease at 60 M is indicated as NS3; upon formation of complexes with
the hexapeptide inhibitor PepA, +A curve, and with the decapeptide in-
hibitor PepC, +C curve.
Fig. 5. Inhibitor-induced conformational change of NS3 as detected by
near-UV circular dichroism. The spectrum of the uncomplexed protease at
60 M is indicated as NS3 and upon formation of complexes with the
decapeptide inhibitors: PepB, +B curve; PepC, +C curve; PepD, +D curve.
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quite similar but not superimposable. In particular PepC
binding causes a larger increase of the intensity of the nega-
tive bands between 255 and 272 nm, whereas PepB and
PepD slightly differ between 260 and 270 nm. Although
these differences are quite marginal, they suggest again that
slightly different rearrangements are possible for various
P-binding sequences.
Therefore, whereas only one enzyme structure was at-
tained for the ternary complex of hexapeptide product in-
hibitors binding in the S site, binding to the S site by P-P
spanning inhibitors is linked to the stabilization of different
tertiary structures of the NS3/4A enzyme. Thus different
binding modes are possible when binding to the S site.
Discussion
In the last few years, many efforts have been directed to-
ward the study of viral proteases as therapeutic targets for
the development of antiviral agents. Viral proteases have
usually a broad specificity, binding and cleaving a wide
range of different peptide substrates. The mechanism by
which a broad specificity can be accomplished is starting to
emerge by a number of reports on different viral proteases,
like HIV aspartic protease, the HCMV serine protease
(LaPlante et al. 1999b), and also in the case of the NS3
serine protease of HCV (Bianchi et al. 1999; Barbato et al.
2000). A key feature of these enzymes is that they can be
considered as a statistical ensemble of conformations, rap-
idly interconverting structures with different states popu-
lated according to their free energies.
In particular, some domains in the HIV protease, such as
the flap regions that are in close contact with the substrate
binding site, are known to possess extraordinarily high flex-
ibility in the substrate-free situation. This inherent basal
flexibility is a key requisite for accomodating different se-
quences where substrate recognition is mediated by a
mechanism of stabilization of conformational states. The
binding of a ligand, a substrate, or an inhibitor plays an
important role in modulating the distribution of states of a
protease by stabilizing certain conformations. In particular,
in the case of HIV protease the binding of the inhibitor may
have a significant effect on the binding site, becoming more
structurally stable. Moreover, the stabilization also propa-
gates to regions not in direct contact with the inhibitor
through cooperative pathways within the protease molecule
(Todd and Freire 1999).
In the case of the hepatitis C virus, the serine protease
domain of NS3 folds into two six-stranded -barrel, trypsin-
like domains with the active site in a crevice between the
two domains (Fig.1). The S-binding region is contained in
the C-terminal -barrel, whereas the S region is in the
N-terminal -barrel. Analysis in solution by circular dichro-
ism spectroscopy and limited proteolysis-mass spectrometry
have shed some insights on the mechanism of binding of
both the NS4A cofactor and product inhibitors (Bianchi et
al. 1997, 1999; Orru` et al. 1999). The binding of the cofac-
tor induces a large conformational rearrangement in the ter-
tiary structure of NS3, whereas the secondary structure is
not perturbed. As a consequence of this structural change
the enzyme becomes more compact and stable. Also the
stabilization effect propagates toward regions remote from
the cofactor binding site like the C-terminal domain. How-
ever, upon NS4A complexation, NS3 is not protected
against proteolytic digestion at specific sites, essentially lo-
cated at the extreme N-terminal region at residues 6, 11, 21,
Fig. 7. Inhibitor-induced conformational change of the NS3/4A complex
as detected by near-UV circular dichroism. The spectrum of the NS3/4A
protease is indicated as NS3/4A, and those of the complex with the inhibi-
tors as PepB, +B curve; PepC, +C curve; and PepD, +D curve.
Fig. 6. Inhibitor-induced conformational change of the NS3/4A complex
as detected by near-UV circular dichroism. The spectrum of the NS3/4A
protease at 60 M is indicated as NS3/4A; upon formation of complexes
with the hexapeptide inhibitor PepA, +A curve, and with the decapeptide
inhibitor PepC, +C curve.
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24, and 26 and at the substrate binding site, residues 134,
154, and 159.
The binding of product inhibitors causes a structural
change in NS3 (Bianchi et al. 1999). In the absence of
cofactor, different binding modes are apparent, while in the
presence of cofactor, all product-inhibitors show the same
binding mode with a small rearrangement of NS3 tertiary
structure. The binding of the cofactor induces an NS3/4A
conformation that is already preorganized for substrate
binding. However, occupancy of the S substrate binding site
induces further structural rearrangements and an overall sta-
bilization of the enzyme complex, which influences also the
N-terminal region, which is directly implicated in cofactor
binding. Therefore, we postulated that only through compl-
exation of both the cofactor and the substrate, a fully com-
petent enzyme is attained.
Our studies are in agreement with the recently published
NMR studies on NS3 (Barbato et al. 2000). Despite the fact
that the catalytic triad is better ordered in the presence of the
NS4A cofactor, a key role in the correct alignment of the
catalytic residues seems to be due to the interaction of the
protease with the substrate. NMR studies on the single-
chain NS3/4A show that the cofactor has a key role in the
stabilization of the N-terminal domain (McCoy et al. 2001).
However model-free dynamics of the complex reveals re-
sidual extensive millisecond–microsecond motion through-
out the N-terminal domain. This is particularly true at the
level of the same residues that are mostly affected by NS4A
binding, suggesting a slow conformation exchange between
the NS3–NS3/4A complex. Moreover in the complex, the
N-terminal 28 residues of the NS3 protease are still en-
dowed with high conformational flexibility.
Among studies of protease inhibitors, there are only a few
examples of inhibitors that make contacts with the S region
of the enzyme (Imperiali and Abeles 1987; Eichler and
Houghton 1993; Landro et al. 1997). In the case of HCV
NS3/4A, the contribution to binding of the P region from a
natural cleavage site is small. This is because noncleavable
substrate analogs extract most of their binding energy from
the P side (Landro et al. 1997). An inhibitor taking advan-
tage of S-binding could therefore display a range of inter-
actions with the enzyme different from the substrate and
represent a novel class of NS3/4A inhibitors. Our combina-
torial investigation of the P2-P4 residues yielded inhibi-
tors whose potency is >600-fold with respect to inhibitors
containing the natural P2-P4 moiety (Ingallinella et al.
2000). The recently developed P-P inhibitors are a useful
structural probe to investigate the binding in the S site of
the protease.
The S region is contained in the N-terminal domain,
which is quite unstructured in the absence of 4A. The near-
UV CD spectroscopy shows that in the cofactor-free NS3,
binding of decapeptide inhibitors has an effect on the pro-
tease tertiary structure. The comparative analysis with in-
hibitors, binding only in the S site, suggests that there are
additional structural rearrangements that are linked to the
binding in the S region. Moreover, these rearrangements
differ among inhibitors that have different P sequences.
Despite the fact that the S is not organized in the cofactor-
free protease, showing a large conformational freedom, the
decapeptide inhibitors can still make contacts in this region
by modulating the distribution of states of NS3 and by sta-
bilizing different conformations. These are also reflected by
the data of limited proteolysis on the decapeptide/NS3 com-
plexes. The preferential cleavage sites in NS3 are essentially
located at the extreme N-terminal region, with residues Tyr
6, Leu 21, and Leu36, and in the C domain near the sub-
strate binding site, Tyr 134, Phe 154, and Cys 159. Upon
inhibitor binding, all the complexes are generally more
compact and stable and therefore it is necessary to increase
the ratio of proteolytic enzyme (chymotrypsin) to substrate
(NS3) to observe the same proteolytic pattern shown by
NS3.
In particular for the P-optimized PepC, complete protec-
tion is observed for Leu 21, Leu 36, and Tyr 134 sites and
partial protection for Phe 154 and Cys 159. Therefore, the
CD and limited-proteolysis data strongly suggest that apart
from the cofactor there is a major role played by the occu-
pancy of the substrate binding site in the structural organi-
zation and activation of the protease with effects that propa-
gate to regions located outside the binding site.
For the ternary NS3/4A/inhibitor complexes, the com-
parative analysis of CD spectra for inhibitor binding in the
S site and for those in which binding extends to the S site
shows that extra binding to the S site causes a further
rearrangement of tertiary structure of the protease. At vari-
ance with what is observed for P inhibitors, these rearrange-
ments may slightly differ among complexes with decapep-
tides with diffent P-binding sequences. This is true for
different P-natural sequences, as well as the P-optimized
sequence. Therefore, despite cofactor complexation, the N-
terminal domain is still flexible, allowing different confor-
mations. To summarize, different binding modes are pos-
sible when binding to the S site of the NS3/4A enzyme.
The limited proteolysis-mass spectrometry data show that
binding in the S site can have profound effects on the
stabilization of the enzyme. Again upon inhibitor binding,
all the complexes are generally more stable than NS3/4A. In
fact, it is necessary to increase the ratio of the chymotrypsin
to substrate NS3 to observe the proteolytic cleavages. How-
ever, no major differences in the stabilization are observed
between the P inhibitor PepA and the P-P inhibitor PepB.
This is probably the result of the poor contribution to the
binding energy by the P natural sequence of PepB. Con-
versely the presence of the C-terminal carboxylate in PepA,
as an important binding determinant for the P inhibitor that
lacks in P-P inhibitors could induce a strong stabilization of
the active site. In particular, in our previous work, we
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showed that binding in the S site, located in the C-terminal
domain, also gave important contributions to the stabiliza-
tion of the N-terminal domain that comprises the Pep4A
cofactor binding site, as well as the S site. However, a
residual flexibility of the N-terminal portion, in particular of
the last two strands, has always been observed both in the
NS3/4A complex and the P-inhibitor/NS3/4A complex. So-
lution structural analysis by NMR has recently confirmed
the large conformational freedom endowed with this portion
of the enzyme in the single-chain NS3/4A protease (McCoy
et al. 2001). Conversely, in the case of the decapeptide
PepC, whose sequence was investigated by combinatorial
chemistry using nonnatural amino acids, the binding of P is
associated with a structural rearrangement of the NS3 struc-
ture. A remarkable stabilization is observed not only for the
active site, but also, for the first time, for the N-terminal
region, in particular for Tyr 6 and Leu 21. From Figure 1
these sites are located in the same region involved in the
cofactor binding, to which the S site also belongs, but are
not in direct contact with the inhibitor.
In summary, our work shows that, as shown for other
viral proteases, there are regions within the HCV NS3 pro-
tease, in particular the active site and the N-terminal do-
main, with less structural stability. The presence of this
residual flexibility in a viral enzyme is important for medi-
ating broad substrate specificity where substrate recognition
is mediated by a mechanism of stabilization of conforma-
tional states. It was possible to develop inhibitors that target
different sites on the protease surface in S and S, also
taking advantage of binding pockets present in the active
site that are not exploited by the natural HCV substrates
(Landro et al. 1997; Urbani et al. 1997; Zhang et al. 1997).
Binding leads as a consequence to an overall stabilization of
the enzyme that propagates to regions not in direct contact
with the inhibitor. Differently from what has been observed
in the case of binding in the S site of the NS3/4A protease,
binding in the S site may stabilize different final states of
the protease. The development of these inhibitors, which
can be considered as belonging to different classes, expands
the opportunities for an effective therapy against the viral
proteases. A detailed understanding of the interactions be-
tween the protease and the inhibitors is required to address
the issue of the most likely outcome of a clinical therapy
with protease inhibitors, that is, viral resistance. An effec-
tive therapy against a viral protease would be achieved ei-
ther by a combination of inhibitors of different classes or by
the search among them for those that evade viral resistance
(Rosin et al. 1999; Todd and Freire 1999; Dauber 2002).
Materials and methods
Enzyme preparation
The protease domain of the HCV J strain NS3 protein (amino acids
1027–1206, followed by the sequence ASKKKK) was prepared
and purified as previously described (Bianchi et al. 1997; Stein-
kühler et al. 1998). The enzyme preparation was analyzed by mass
spectrometry performed on HPLC-purified samples using a Per-
kin-Elmer API 100 instrument, and N-terminal sequence analysis
was carried out using Edman degradation on an Applied Biosys-
tems Model 470A gas-phase sequencer. The NS3 J preparation
consisted of two components. The minor species corresponded to
the intact 1–186 protease (MW 19743.1 +/− 1.5), whereas the
major component showed a molecular mass of 19540.8 +/− 1.1 and
was identified as a truncated form of the protease lacking the
N-terminal dipeptide Met-Ala. Enzyme stocks were quantitated by
amino acid analysis.
Peptide synthesis
Protected amino acids were purchased from Novabiochem, Neo-
system, Bachem, or Synthetech. Peptide synthesis was performed
by Fmoc/t-Bu chemistry (Atherton and Sheppard 1989) on No-
vasyn TGR (peptide amides) resin or on preloaded Fmoc-Cys(Trt)-
Novasyn TGA resin. Peptide assembly was done on a Millipore
9050 Plus synthesizer, using PyBOP/HOBt/DIEA (1:1:2) activa-
tion with a fivefold molar excess of acylant over the resin groups
and 1-h coupling times. The peptides were cleaved with 88% TFA,
5% phenol, 2% triisopropylsilane, and 5% water. Crude peptides
were purified by reverse-phase HPLC on a Nucleosyl C-18,
250 ✕ 21 mm, 100 A, 7 m, using H2O, 0.1% TFA, and acetoni-
trile, 0.1% TFA, as eluents. Analytical HPLC was performed on an
Ultrasphere C-18, 250 ✕ 4.6 mm, 80 Å, 5 m (Beckman). The
purified peptides were characterized by mass spectrometry, [1H]-
NMR, and amino acid analysis.
As protease cofactor, we used the peptide Pep4A, which en-
compasses the central hydrophobic domain of the HCV NS4A
(amino acids 1678–1691 of the HCV polyprotein sequence) with a
three-lysine tag at the N terminus to increase solubility KKKGSV-
VIVGRIILSGR-NH2 (Bianchi et al. 1997). The concentration of
stock solutions of peptides, prepared in buffered aqueous solution,
was determined by quantitative amino acid analysis performed on
HCl-hydrolyzed samples.
Limited-proteolysis experiments
Limited-proteolysis experiments were performed at 25°C, in 50
mM phosphate buffer at pH 7.5, 70 mM NaCl, 2.5 mM DTT, 1%
CHAPS, and 15% glycerol, using chymotrypsin as proteolytic
probe. NS3/inhibitor or NS3/Pep4A/inhibitor complexes were
formed by incubating either NS3 or NS3/Pep4A complex with a
10:1 molar excess of the individual inhibitor at 25°C for 15 min
prior to proteolytic enzyme addition. Each inhibitor complex was
digested using a 1:100 (w/w) enzyme to substrate ratio; NS3 or
NS3/4A complex were digested using a 1:150 (w/w) ratio.
The extent of the enzymatic hydrolysis was monitored on a
time-course basis by sampling the incubation mixtures at appro-
priate time intervals, followed by HPLC fractionation of proteo-
lytic fragments on a Vydac C18 column. Peptides were eluted by
means of a linear gradient from 5% to 65% of acetonitrile in 0.1%
TFA over 73 min. Identification of individual fragment samples
was performed by injecting the HPLC fractions into an electro-
spray ion source (kept at 80°C) at a flow rate of 5 L/min, on a
Bio-Q triple quadrupole mass spectrometer (Micromass). Data
were analyzed using the MASSLYNX program. Mass calibration
was performed by means of the multiply charged ions from a
separate injection of horse heart myoglobin (average molecular
mass 16,951.5 Da); all masses are reported as average mass.
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Circular dichroism spectroscopy
Circular dichroism measurements were performed using a Jasco
J-710 spectropolarimeter equipped with a cell holder thermostati-
cally controlled by a circulating water bath. Measurements were
recorded at 15°C, with an 8-sec time constant and 5 nm/min scan
speed and spectra were averaged for two acquisitions. The protein
concentration was 1.2 mg/mL, and spectra were collected with
rectangular quartz cells of 1-cm path length in the near-UV region
(320–250 nm) and 0.01-cm path length in the far-UV region (250–
190 nm). The concentration of both protein and peptide stock
solutions was determined by quantitative amino acid analysis. Re-
sults are reported as mean residue ellipticity [] having units of deg
cm2 dmol−1 and were calculated using a mean residue weight of
106 Da for NS3. The complexes were formed by incubating the
protease with increasing amounts of the peptide inhibitors either in
the presence or in the absence of Pep4A for 10 min at 15°C. The
complexes were studied in 50 mM sodium phosphate buffer at pH
7.5, 15% glycerol, 2% CHAPS, and 3 mM DTT. Spectra were
recorded before and after the addition of Pep4A and/or inhibitors
and routinely corrected for the background signal and for dilution
effects. By following the ellipticity as a function of peptide con-
centration it was possible to derive a stoichiometry of 1:1 for each
inhibitor with respect to the protease.
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